May 16, 2022 4:05pm EDT Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
Apr 25, 2022 4:50pm EDT Dermata Therapeutics Announces Closing of $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Apr 21, 2022 9:00am EDT Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Mar 28, 2022 8:30am EDT Dermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial Results
Mar 24, 2022 8:30am EDT Dermata Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference
Jan 13, 2022 8:30am EST Dermata Appoints Life Science Executive Brittany Bradrick to Board of Directors
Nov 19, 2021 8:30am EST Dermata Announces Positive Results from DMT410 Phase 1b Proof of Concept Study for Aesthetic Skin Conditions
Nov 17, 2021 8:00am EST Dermata Announces First Patient Enrolled in its Phase 2 Trial of DMT310 for the Treatment of Moderate-to-Severe Rosacea
Nov 15, 2021 4:01pm EST Dermata Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update
